Amgen (AMGN) Projected to Post Quarterly Earnings on Tuesday

Amgen (NASDAQ:AMGN - Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 4th. Analysts expect the company to announce earnings of $5.04 per share and revenue of $8.87 billion for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business earned $4.96 earnings per share. On average, analysts expect Amgen to post $20 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Stock Performance

NASDAQ AMGN traded up $1.40 on Friday, hitting $285.42. 3,799,348 shares of the company traded hands, compared to its average volume of 2,746,697. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The business's 50 day moving average price is $271.06 and its 200-day moving average price is $304.33. The company has a market capitalization of $153.42 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.34%. Amgen's dividend payout ratio (DPR) is currently 121.90%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AMGN shares. Wells Fargo & Company reduced their target price on Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a report on Friday, January 10th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Sanford C. Bernstein began coverage on Amgen in a research report on Thursday, October 17th. They set an "outperform" rating and a $380.00 price target on the stock. Jefferies Financial Group reissued a "buy" rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen has a consensus rating of "Hold" and an average price target of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.